大麻素CB2受体 ортолог;体外功能和前临床到临床翻译的前景
Emma R Carruthers1,2,3, Natasha L Grimsey1,2,3
1Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
尽管临床前有希望,但大麻素CB2受体激动剂在人体上表现出有限的疗效. 人类和动物CB2受体之间的差异可能解释了这一点,影响了疼痛和免疫条件的治疗转化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 大麻素CB2受体激动剂正在研究免疫调节和缓解疼痛.
- 在动物中进行的临床前研究显示出有希望,但人类临床试验的效果有限.
- 人类和动物CB2受体之间的序列差异可能导致不同的连接体相互作用和信号传递.
研究的目的:
- 总结CB2受体结构和比较药理学.
- 审查CB2受体药物的临床前临床翻译挑战.
- 为了突出人类,小鼠和老鼠CB2受体之间的差异.
主要方法:
- 对CB2受体基因和蛋白质结构的比较分析.
- 在不同物种的CB2正义学家中评估分子药理学.
- 对CB2受体治疗的当前临床前到临床翻译数据的审查.
主要成果:
- 人类和动物CB2受体之间存在显著的初级氨基酸序列分歧.
- 在物种之间产生不同的连接体参与和信号反应的潜力.
- 目前CB2药物从临床前环境转化为临床环境的转化是不理想的.
结论:
- 在CB2受体的物种特异性差异对治疗药物开发构成挑战.
- 解决这些分子和药理差异对于成功的翻译至关重要.
- 克服这些挑战的策略可能会提高CB2受体向疗法的疗效.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Preclinical Development: Overview
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Opioid Receptors: Overview
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
